With an anticipated price point of less than Rs 150 per dose, this will be the first time an Indian company will be able to adopt the highly productive C1-cell protein production platform.
The earlier order to process the claims and to make the actual payment of compensation within a period of thirty days from the date of receipt of claim shall continue to be enforced, said the central government.
New research, license and collaboration agreement with Janssen for the development and manufacture of therapeutic proteinsReceived NIIMBL coronavirus grant.
The FINANCIAL - Advancing Dyadic s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial finchannel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finchannel.com Daily Mail and Mail on Sunday newspapers.